Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19441508 | 0.89 | PKM (0.36) | KMT2AALDH1A1LMNAALOX12POLB | |
| SCHEMBL3212559 | 0.87 | KMT2A (0.37) | KMT2AALDH1A1LMNAALOX12POLB | |
| SCHEMBL26883170 | 0.87 | LMNA (0.33) | KMT2AALDH1A1LMNAALOX12POLB | |
| SCHEMBL18632851 | 0.87 | KMT2A (0.32) | KMT2AALDH1A1LMNAALOX12POLB | |
| SCHEMBL2622404 | 0.86 | KMT2A (0.37) | KMT2AALDH1A1LMNAALOX12POLB | |
| SCHEMBL2625534 | 0.86 | KMT2A (0.37) | KMT2AALDH1A1LMNAALOX12POLB | |
| SCHEMBL2625532 | 0.86 | KMT2A (0.37) | KMT2AALDH1A1LMNAALOX12POLB | |
| SCHEMBL19367719 | 0.85 | KMT2A (0.31) | KMT2AALDH1A1LMNAALOX12POLB | |
| SCHEMBL23766537 | 0.82 | KMT2A (0.35) | KMT2AALDH1A1LMNAALOX12POLB | |
| SCHEMBL1267540 | 0.82 | KMT2A (0.39) | KMT2AALDH1A1LMNAALOX12POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12491207-B2 | Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability | VANELTIX PHARMA, INC. (US) | 2025-12-09 | — | — | US | claimed |
| US-20230137384-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. | 2023-05-04 | — | — | US | claimed |
| US-11491179-B2 | Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability | URIGEN PHARMACEUTICALS, INC. (US) | 2022-11-08 | — | — | US | claimed |
| EP-3458490-B1 | POLAR MODIFIER SYSTEMS FOR HIGH VINYL BLOCK COPOLYMERIZATION | DYNASOL ELASTOMEROS SA DE CV (MX) | 2022-11-02 | — | — | EP | claimed |
| US-20220273587-A1 | ALKALIZATION OF URINARY BLADDER WALL PRIOR TO TREATMENT WITH INTRAVESICAL HEPARIN AND ALKALINIZED LIDOCAINE TO ENHANCE RELIEF OF BLADDER PAIN SYMPTOMS | PARSONS C LOWELL (US) | 2022-09-01 | — | — | US | claimed |
| CN-111032697-B | In situ polymer blends for tires | 盛禧奥欧洲有限责任公司 | 2022-07-05 | — | — | CN | claimed |
| US-20200131358-A1 | In-Situ Polymer Blend for a Tire | SYNTHOS DWORY 7 SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (PL) | 2020-04-30 | — | — | US | claimed |
| CN-111032697-A | In situ polymer blends for tires | 盛禧奥欧洲有限责任公司 | 2020-04-17 | — | — | CN | claimed |
| WO-2019020417-A1 | IN-SITU POLYMER BLEND FOR A TIRE | TRINSEO EUROPE GMBH (CH) | 2019-01-31 | — | — | WO | claimed |
| EP-3434697-A1 | IN-SITU POLYMER BLEND FOR A TIRE | Trinseo Europe GmbH (CH) | 2019-01-30 | — | — | EP | claimed |
| US-20260144842-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | TEMPLE OTORONGO LLC (US) | 2026-05-28 | — | — | US | disclosed |
| US-12491207-B2 | Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability | VANELTIX PHARMA, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| EP-3523274-B1 | FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE | ORBUS THERAPEUTICS INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12357604-B2 | Topical formulations of cannabinoids and use thereof in the treatment of pain | INMED PHARMACEUTICALS INC. (CA) | 2025-07-15 | — | — | US | disclosed |
| US-20250127762-A1 | ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITIS | TARSUS PHARMACEUTICALS, INC. | 2025-04-24 | — | — | US | disclosed |
| EP-1245585-A2 | Hydrogenated modified polymer, process for producing the same and composition containing the same | JSR Corporation (JP) | 2002-10-02 | — | — | EP | disclosed |
| US-6362272-B1 | CONJUGATED DIOLEFIN AND AROMATIC VINYL COPOLYMER | JSR CORPORATION (JP) | 2002-03-26 | — | — | US | disclosed |
| US-6191234-B1 | CONJUGATED DIENE-AROMATIC VINYL COPOLYMER OBTAINED BY MODIFYING POLYMER WITH A AMINO GROUP IS USED TO IMPROVE WET SKID RESISTANCE, WEAR RESISTANCE OF AUTOMOBILE TIRE TREAD | JSR CORPORATION (JP) | 2001-02-20 | — | — | US | disclosed |
| EP-0992537-A1 | Oil extended rubber and rubber composition | JSR Corporation (JP) | 2000-04-12 | — | — | EP | disclosed |
| EP-0924227-A1 | Conjugated diolefin-based copolymer rubber and composition thereof | JSR Corporation (JP) | 1999-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144842-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | OPRK1, TPH1, HTR3C | KMT2A 4104/4885ALDH1A1 3225/4885LMNA 1796/4885 |
| US-12491207-B2 | Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability | OGFR, ALOX5, PTGS1 | KMT2A 4584/4885ALDH1A1 2745/4885LMNA 4660/4885 |
| US-12357604-B2 | Topical formulations of cannabinoids and use thereof in the treatment of pain | CNR2, CNR1, LCAT | KMT2A 2406/4885ALDH1A1 4229/4885LMNA 261/4885 |
| US-20230137384-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | OGFR, ALOX5, PTGS1 | KMT2A 4584/4885ALDH1A1 2745/4885LMNA 4660/4885 |
| US-11491179-B2 | Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability | OGFR, ALOX5, PTGS1 | KMT2A 4584/4885ALDH1A1 2745/4885LMNA 4660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.